Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Preliminary promise for venetoclax and 3+7 in untreated AML

Daniel DeAngelo • 10 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin Venetoclax

The results of a phase 1 trial (NCT03709758) of escalating doses of venetoclax with daunorubicin/cytarabine (7+3) induction and high dose cytarabine consolidation in untreated adults acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Here Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the preliminary results, which show promise.

More from Daniel DeAngelo

1:36
IMGN632: a novel CD123-targeted antibody-drug conjugate for R/R BPDCN
Daniel DeAngelo • 3 Dec 2020
1:36
Diagnostic pathology is crucial to guide treatment options
Daniel DeAngelo • 3 Dec 2020
2:29
ASH 2020: Treatment advances in mastocytosis
Daniel DeAngelo • 3 Dec 2020
3:57
Major ALL treatment updates at ASH 2020
Daniel DeAngelo • 3 Dec 2020

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals